Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.
Multiple myeloma (MM) is characterized by increased numbers of malignant plasma cells. Plasma cells, that represent the terminal differentiation of B lymphocytes, have considerable heterogeneity of surface markers expressed on them. Some studies showed the prognostic significance of several immunophenotypic molecules on MM cells. Here, we review several surface markers related to their prognostic significance in MM patients. We also report that CD56-negative MM is the unique entity characterized by poor prognosis with high incidence of extramedullary disease, Bence Jones protein, renal insufficiency, thrombocytopenia and plasmablastic morphology.
Sahara
Naohi
N
Internal Medicine III, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu-shi, 431-3192, Japan. sahara@hama-med.ac.jp
Takeshita
Akihiro
A
D014408:Biomarkers, Tumor / Q000378:metabolism*; D019002:CD56 Antigen / Q000378:metabolism*; D006801:Humans; D016023:Integrins / Q000378:metabolism; D009101:Multiple Myeloma / Q000378:metabolism*; D019006:Neural Cell Adhesion Molecules / Q000378:metabolism; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000378:metabolism
D014408:Biomarkers, Tumor; D019002:CD56 Antigen; D016023:Integrins; D019006:Neural Cell Adhesion Molecules; D019947:Receptors, Interleukin-6